围手术期化疗与放疗对原发性肢体软组织肉瘤患者的影响:跨主要组织学亚型与主要参考中心的回顾性分析
该回顾性分析纳入四个参考中心20年间的3752例原发性肢体软组织肉瘤患者,中位随访79个月。结果显示中心和組織学类型显著影响放化疗的实施;放疗与更好的局部结局相关(尤其在黏液样脂肪肉瘤、血管肉瘤和黏液纤维肉瘤),化疗不是所有患者总生存的独立预后因素(p=0.73),倾向评分匹配后化疗组生存更长但未达统计学显著(p=0.054)。
要点
- 中心和組織学类型显著影响肢体软组织肉瘤患者围手术期放化疗的实施。
- 放疗与更好的局部结局相关,尤其在黏液样脂肪肉瘤、血管肉瘤和黏液纤维肉瘤。
- 化疗不是所有患者总生存的独立预后因素(p=0.73),匹配分析生存差异未达显著(p=0.054)。
核心结论
- 部分組織学类型从围手术期放疗中获得更大的局部复发风险降低获益。
- 化疗相关的5%生存获益趋势与已发表文献一致,但确定性结论有待正在进行的随机对照试验。
- 原发性肢体软组织肉瘤的围手术期化疗不损害远处转移后的生存。
研究设计与样本
- 回顾性分析,纳入三个欧洲和一个北美参考中心20年间连续治疗的所有原发性肢体软组织肉瘤患者,共3752例。
- 中位随访79个月(四分位距44-119)。
- 采用多变量二元逻辑回归模型探索化疗/放疗的实施倾向,采用倾向评分匹配分析探索化疗效果。
主要发现
- 中心和組織学类型显著影响放疗/化疗的实施。
- 放疗与更好的局部结局相关,尤其在黏液样脂肪肉瘤、血管肉瘤和黏液纤维肉瘤,但与生存无关。
- 化疗不是所有患者总生存的独立预后因素(p=0.73)。
- 倾向评分匹配分析中,接受化疗的患者生存更长,但差异未达统计学显著(p=0.054)。
关键数值与推荐
- 化疗不是所有患者总生存的独立预后因素,p=0.73。
- 倾向评分匹配分析中化疗组生存更长但未达统计学显著,p=0.054。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The role of radiotherapy (RTx) and chemotherapy (CTx) in primary extremity soft tissue sarcoma (eSTS) patients is not precisely defined. METHODS: All consecutive primary eSTS patients treated within three European and one North American reference centres in a 20-year time span were included. The tendency to perform chemotherapy/radiotherapy (CTx/RTx) was explored using multivariable binary logistic models. Five and 10-year overall survival (OS) and crude cumulative incidence (CCI) of local recurrence (LR) and distant metastasis (DM) were estimated. Multivariable analyses of OS, CCI of LR and CCI of DM were performed. The effect of CTx administration was explored with a propensity score matching analysis. RESULTS: Overall, 3752 patients were included. Median follow-up was 79 months (interquartile range 44-119). Ten-year OS, CCI of LR and CCI of DM were 66.3% (64.3-68.2%), 8.2% (7.2-9.2%) and 28.2% (26.6-30.0%), respectively. Centre and histology significantly influenced administration of RTx/CTx. RTx was associated with a better local outcome, especially in myxoid liposarcoma, vascular sarcoma and myxofibrosarcoma, without being associated with survival. Chemotherapy was not an independent prognostic factor for OS in all patients (p = 0.73). In a propensity score-matched analysis, patients treated with CTx had longer survival although this difference did not reach statistical significance (p = 0.054). The use of perioperative CTx in patients with primary localised eSTS was not associated with worse survival after occurrence of DM. CONCLUSION: Some histologies gain a greater benefit from perioperative RTx in terms of LR risk reduction. The trend towards a 5% survival benefit associated with CTx administration is consistent with the published literature, but definitive conclusions are awaited from ongoing randomised controlled trials. Perioperative CTx for primary eSTS does not hamper post-DM survival.
引用
- Callegaro D, Miceli R, Bonvalot S, et al. Impact of perioperative chemotherapy and radiotherapy in patients with primary extremity soft tissue sarcoma: retrospective analysis across major histological subtypes and major reference centres. Eur J Cancer. 2018. PMID: 30384013. doi:10.1016/j.ejca.2018.09.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。